DexCom, Inc. (NASDAQ:DXCM) today announced the appointment of Eric
Topol, M.D. as a member of DexCom’s Board of Directors.
Dr. Topol is the Director of the Scripps Translational Science
Institute, a National Institutes of Health funded program of the
Clinical and Translational Science Award Consortium. In 2009, he was
named the Gary and Mary West Endowed Chair of Innovative Medicine. He is
Professor of Translational Genomics at The Scripps Research Institute,
the Chief Academic Officer of Scripps Health, and a Senior Consultant
cardiologist practitioner at Scripps Clinic.
“Eric is one of the most respected and successful leaders in the medical
field. We recruited Eric to the board of directors for his breadth of
experience and history of driving innovation in the complex and dynamic
healthcare environment” said Terry Gregg, President and Chief Executive
Officer of DexCom.
Prior to Scripps, Dr. Topol served on the faculty of Case Western as a
professor in genetics, chaired the Department of Cardiovascular Medicine
at Cleveland Clinic for fifteen years and raised its status to rank
number one by the US News and World Report for 11 consecutive years. He
also founded the Cleveland Clinic Lerner College of Medicine.
Dr. Topol has also been a medical innovator in wireless medicine. He
served on the Scientific Advisory Board of Cardionet, and currently is
on the Board of Directors of Triage Wireless. He is the Chief Medical
Officer and Founding Board Member of the newly established Gary and Mary
West Wireless Health Institute.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and
marketing continuous glucose monitoring systems for ambulatory use by
patients and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history.
Successful commercialization of the company’s products is subject to
numerous risks and uncertainties, including a lack of acceptance in the
marketplace by physicians and patients, the inability to manufacture
products in commercial quantities at an acceptable cost, possible delays
in the company’s development programs, the inability of patients to
receive reimbursements from third-party payors and inadequate financial
and other resources. Certain of these risks and uncertainties, in
addition to other risks, are more fully described in the company’s
quarterly report on Form 10-Q for the period ending March 31, 2009, as
filed with the Securities and Exchange Commission on May 6, 2009.
DexCom, Inc.
Steve Pacelli
Chief Administrative Officer
(858) 200-0200
